Skip to main content
. 2018 Mar 14;10(4):e8347. doi: 10.15252/emmm.201708347

Figure 7. SRB1 in clinical prostate cancer.

Figure 7

  1. Representative SRB1 immunostained images of prostate cancer samples. High SRB1 (n = 47) represents patients with SR‐B1 IHC score above median, and low SRB1 (n = 43) represents patients with SR‐B1 IHC score below median (scale bar = 10 μm).
  2. Kaplan–Meier plot for relapse‐free survival of ADT‐treated prostate cancer patients (SRB1‐high patients = 11; SRB1‐low patients = 11; log‐rank Mantel–Cox test; P = 0.006).
  3. Kaplan–Meier plot for overall (post‐diagnosis) survival of patients treated with ADT (SRB1‐high patients, n = 12; SRB1‐low patients, n = 16; log‐rank Mantel–Cox test; P = 0.0354).
  4. SPRY2 deficiency facilitates progression of prostate cancer to CRPC through HER2‐mediated induction of IL6, HSD3B1 and SRB1. IL6 cytokine axis, in a paracrine manner, induces host adipose lipolysis and hepatic cholesterol synthesis, resulting in increased circulating cholesterol. ADT‐resistant tumours take up cholesterol through SRB1 for androgen biosynthesis. Normalising the systemic cholesterol homeostasis by statins and blocking SRB1‐mediated cholesterol uptake by tumours may serve as potential approaches to diminish treatment resistance in a subset of prostate cancers with the SPRY2 deficiency or HER2 activation.